BUDGET IMPACT ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA

被引：0
|
作者：
Djambazov, S. [1 ]
Slavchev, G. [1 ]
Velchev, M. [2 ]
Vekov, T. [3 ]
机构：
[1] HTA Ltd, Sofia, Bulgaria
[2] Pfizer Luxembourg SARL Branch Bulgaria, Sofia, Bulgaria
[3] Med Univ Pleven, Pleven, Bulgaria
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.135
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN57
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
  • [32] Breast cancer specific quality of life in HR+/HER2-advanced/metastatic breast cancer patients in a real-world setting.
    Wood, Robert
    Mitra, Debanjali
    De Courcy, Jonathan
    Iyer, Shrividya
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Palbociclib versus abemaciclib in HR+/HER2-advanced breast cancer: an indirect comparison of patient-reported end points
    Law, Ernest
    Gavanji, Roya
    Walsh, Sarah
    Haltner, Anja
    McTavish, Rebecca
    Cameron, Chris
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (02) : 109 - 120
  • [34] Palbociclib Plus Fulvestrant Maintains Long-Term Overall Survival Benefit in HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S5 - S6
  • [35] HR+/HER2-Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
    Jerzak, Katarzyna J.
    Bouganim, Nathaniel
    Brezden-Masley, Christine
    Edwards, Scott
    Gelmon, Karen
    Henning, Jan-Willem
    Hilton, John F.
    Sehdev, Sandeep
    CURRENT ONCOLOGY, 2023, 30 (06) : 5425 - 5447
  • [36] Current treatment landscape of HR+/HER2-advanced breast cancer in the Nordics: a modified Delphi study
    Geisler, Jurgen
    Karihtala, Peeter
    Tuxen, Malgorzata
    Valachis, Antonis
    Holm, Barbro
    ACTA ONCOLOGICA, 2023, 62 (12) : 1680 - 1688
  • [37] Current treatment landscape of HR+/HER2-advanced breast cancer in the Nordics: A modified Delphi study
    Karihtala, P.
    Valachis, A.
    Tuxen, M.
    Geisler, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S218 - S218
  • [38] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [39] Palbociclib plus endocrine therapy in older women with HR+/HER2-advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
    Rugo, Hope S.
    Turner, Nicholas C.
    Finn, Richard S.
    Joy, Anil A.
    Verma, Sunil
    Harbeck, Nadia
    Masuda, Norikazu
    Im, Seock-Ah
    Huang, Xin
    Kim, Sindy
    Sun, Wan
    Iyer, Shrividya
    Schnell, Patrick
    Bartlett, Cynthia Huang
    Johnston, Stephen
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : 123 - 133
  • [40] A systematic literature review of prognostic factors in patients with HR+/HER2-advanced breast cancer in Japan
    Hattori, Masaya
    Novick, Diego
    Takaura, Kana
    Tanizawa, Yoshinori
    Kawaguchi, Tsutomu
    Haro, Josep Maria
    Monistrol-Mula, Anna
    Onishi, Akira
    Iwata, Hiroji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (10) : 1498 - 1508
12345